Whereas in low- and middle-income countries, inadequate access to insulin [25, 26] and oral drugs for controlling glucose and blood pressure represent the main bottleneck in type 2 diabetes treatment; in high-income countries, main problems relate to lifestyle and are correlated with nutrition, exercise habits and obesogenic living environments [27]. This evidence concerns the gene INS and type 2 diabetes mellitus.